(Q33395607)

26 July 2017

title

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma (English)

1 reference

26 July 2017

3

Brianna N Harris

1 reference

26 July 2017

12

Paul G Richardson

1 reference

26 July 2017

8

Kenneth C Anderson

1 reference

26 July 2017

2

Nikhil C Munshi

1 reference

26 July 2017

1

Irene M Ghobrial

1 reference

26 July 2017

7

Jacob P Laubach

1 reference

26 July 2017

6

Robert L Schlossman

1 reference

26 July 2017

Peipei Shi

4

1 reference

26 July 2017

Nichole M Porter

5

1 reference

26 July 2017

Durisala Desaiah

9

1 reference

26 July 2017

Scott P Myrand

10

1 reference

26 July 2017

James E Wooldridge

11

1 reference

26 July 2017

Rafat Abonour

13

1 reference

26 July 2017

publication date

31 May 2011

1 reference

American Journal of Hematology

26 July 2017

published in

1 reference

26 July 2017

volume

86

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

573-578

1 reference

26 July 2017

cites work

Cancer statistics, 2010

1 reference

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

21 January 2018

1 reference

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma

21 January 2018

1 reference

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

21 January 2018

1 reference

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

21 January 2018

1 reference

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

21 January 2018

1 reference

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.22048

1 reference

26 July 2017

1 reference